MétaCan
Menu
Back to cohort
Record W4376129366 · doi:10.1016/j.pcad.2023.05.002

Biomarkers for the Diagnosis of Heart Failure in People with Diabetes: A Consensus Report from Diabetes Technology Society

2023· review· en· W4376129366 on OpenAlexaff
Andrea M. Yeung, Jingtong Huang, Ambarish Pandey, Ibrahim A. Hashim, David Kerr, Rodica Pop‐Busui, Connie M. Rhee, Viral N. Shah, Lia Bally, Antoni Bayés‐Genís, Yong Mong Bee, Richard M. Bergenstal, Javed Butler, G. Alexander Fleming, Gregory H. Gilbert, Stephen J. Greene, Mikhail Kosiborod, Lawrence A. Leiter, Boris Mankovsky, Thomas W. Martens, Chantal Mathieu, Viswanathan Mohan, Kershaw V. Patel, Anne L. Peters, Eun‐Jung Rhee, Giuseppe Rosano, David B. Sacks, Yader Sandoval, Jane Jeffrie Seley, Oliver Schnell, Guillermo E. Umpierrez, Kayo Waki, Eugene E. Wright, Alan H.B. Wu, David C. Klonoff

Bibliographic record

VenueProgress in Cardiovascular Diseases · 2023
Typereview
Languageen
FieldMedicine
TopicHeart Failure Treatment and Management
Canadian institutionsUniversity of TorontoSt. Michael's Hospital
FundersNational Institute on Minority Health and Health DisparitiesNational Institute on AgingRelypsaDexcomNational Institutes of HealthEsperion TherapeuticsGilead SciencesServierImpulse DynamicsTandem Diabetes CareNovo NordiskReCor MedicalCytokineticsMannKind CorporationPfizerInsulet CorporationVifor PharmaLivaNovaEli Lilly and CompanyBristol-Myers SquibbAstraZenecaAmgenAmerican RegentKowa CompanySanofiAmerican Heart Association
KeywordsMedicineBiomarkerDiabetologyNatriuretic peptideIntensive care medicineDiabetes mellitusInternal medicineType 2 diabetesHeart failureStage (stratigraphy)AsymptomaticEndocrinology

Abstract

fetched live from OpenAlex

Diabetes Technology Society assembled a panel of clinician experts in diabetology, cardiology, clinical chemistry, nephrology, and primary care to review the current evidence on biomarker screening of people with diabetes (PWD) for heart failure (HF), who are, by definition, at risk for HF (Stage A HF). This consensus report reviews features of HF in PWD from the perspectives of 1) epidemiology, 2) classification of stages, 3) pathophysiology, 4) biomarkers for diagnosing, 5) biomarker assays, 6) diagnostic accuracy of biomarkers, 7) benefits of biomarker screening, 8) consensus recommendations for biomarker screening, 9) stratification of Stage B HF, 10) echocardiographic screening, 11) management of Stage A and Stage B HF, and 12) future directions. The Diabetes Technology Society panel recommends 1) biomarker screening with one of two circulating natriuretic peptides (B-type natriuretic peptide or N-terminal prohormone of B-type natriuretic peptide), 2) beginning screening five years following diagnosis of type 1 diabetes (T1D) and at the diagnosis of type 2 diabetes (T2D), 3) beginning routine screening no earlier than at age 30 years for T1D (irrespective of age of diagnosis) and at any age for T2D, 4) screening annually, and 5) testing any time of day. The panel also recommends that an abnormal biomarker test defines asymptomatic preclinical HF (Stage B HF). This diagnosis requires follow-up using transthoracic echocardiography for classification into one of four subcategories of Stage B HF, corresponding to risk of progression to symptomatic clinical HF (Stage C HF). These recommendations will allow identification and management of Stage A and Stage B HF in PWD to prevent progression to Stage C HF or advanced HF (Stage D HF).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.929
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0000.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.026
GPT teacher head0.307
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueProgress in Cardiovascular DiseasesSame topicHeart Failure Treatment and ManagementFrench-language works237,207